Cargando…

Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report

Anti-melanoma differentiation-associated protein 5 (MDA5)-positive rapidly progressive interstitial lung disease (RP-ILD) is associated with poor prognosis, and the most effective therapeutic intervention has not been established. Herein we report a case of a 45-year-old female patient who presented...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yen, Tsai-Hung, Tseng, Chih-Wei, Wang, Kao-Lun, Fu, Pin-Kuei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708605/ https://www.ncbi.nlm.nih.gov/pubmed/34946303 http://dx.doi.org/10.3390/medicina57121358

Ejemplares similares

Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib
por: Luo, Man, et al.
Publicado: (2022)

Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib
por: Jiang, Zong, et al.
Publicado: (2023)

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis
por: Ida, Tomoaki, et al.
Publicado: (2023)

Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis
por: Li, Ting, et al.
Publicado: (2016)

A New Predictive Model for the Prognosis of MDA5(+) DM-ILD
por: Niu, Qian, et al.
Publicado: (2022)

Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease
por: Scirocco, Chiara, et al.
Publicado: (2020)

ChILD – Children's interstitial lung disease
Publicado: (2018)

Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease—an Auckland case series
por: Dick, Michael, et al.
Publicado: (2021)

Anti-MDA5 Associated Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Lung Disease
por: Tavakolian, Kameron, et al.
Publicado: (2022)

Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
por: Nishi, Kentaro, et al.
Publicado: (2022)

Interstitial lung disease (ILD) in India: Insights and lessons from the prospective, landmark ILD-India registry
por: Raghu, Ganesh, et al.
Publicado: (2016)

Impact of progressive fibrosing interstitial lung disease (ILD) in ILD patients complicated with secondary spontaneous pneumothorax
por: Yamakawa, Hideaki, et al.
Publicado: (2021)

Roles of biomarkers in anti‐MDA5‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease
por: Li, Xiaomeng, et al.
Publicado: (2022)

Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review
por: Ogawa, Yuka, et al.
Publicado: (2017)

Correction: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
por: Nishi, Kentaro, et al.
Publicado: (2022)

RP-HPLC and UV Spectrophotometric Methods for Estimation of Pirfenidone in Pharmaceutical Formulations
por: Parmar, V. K., et al.
Publicado: (2014)

P14 Challenges in treating anti-melanoma differentiation associated gene 5 (MDA5) antibody positive juvenile dermatomyositis (JDM) with interstitial lung disease (ILD) complicated by pneumocytis jirovecii pneumonia (PCP): a case report
por: Affendi, Sharifah Adrianna, et al.
Publicado: (2022)

Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
por: Ikeda, Satoshi, et al.
Publicado: (2015)

2. Two cases of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease
por: Levasseur, Kirsty, et al.
Publicado: (2019)

Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
por: Aissaoui, Houari, et al.
Publicado: (2021)

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)
por: Jee, Adelle S., et al.
Publicado: (2017)

7. Anti-MDA5 associated dermatomyositis
por: Laverty, Ursula, et al.
Publicado: (2019)

Editorial: Anti-MDA5-Positive Dermatomyositis
por: Gono, Takahisa, et al.
Publicado: (2022)

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
por: Cottin, Vincent, et al.
Publicado: (2019)

Children’s Interstitial and Diffuse Lung Diseases (ChILD) in 2020
por: Ferraro, Valentina Agnese, et al.
Publicado: (2020)

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
por: Copeland, Carla R., et al.
Publicado: (2021)

Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases
por: Mehta, Asmita A, et al.
Publicado: (2021)

Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model
por: Guo, Jinqiang, et al.
Publicado: (2023)

Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan
por: Tokunaga, Kenichiro, et al.
Publicado: (2017)

Effects of pirfenidone on renal function in patients with interstitial pneumonia
por: Matsumoto, Jun, et al.
Publicado: (2021)

Pneumomediastinum in MDA5-associated clinically amyopathic dermatomyositis
por: Kotsiou, Ourania S., et al.
Publicado: (2017)

Therapiealternativen bei amyopathischer MDA5-positiver Dermatomyositis
por: Schumacher, Falk, et al.
Publicado: (2023)

Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
por: Sakamoto, Noriho, et al.
Publicado: (2018)

Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis Complicated by Unilateral Right-sided Interstitial Lung Disease
por: Kori, Mayuko, et al.
Publicado: (2020)

Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease
por: Liang, Lin, et al.
Publicado: (2021)

A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis
por: Xu, Wenwen, et al.
Publicado: (2021)

Clinically amyopathic dermatomyositis with interstitial lung disease double-positive for anti-MDA5 and anti-PL12 antibodies
por: Hiramatsu, Toshiya, et al.
Publicado: (2022)

Panniculitis as the Transformed Cutaneous Manifestation of Refractory Dermatomyositis with Successful Management with Tofacitinib
por: Rathore, Upendra, et al.
Publicado: (2022)

Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report
por: Conca, Walter, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_njrncfo8stjdjk29qdo318cs4f